Cantor Fitzgerald Initiates Coverage On Eloxx Pharma with Overweight Rating
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsInitiation
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Overweight rating.
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Overweight rating.